Financials Tianjin Chase Sun Pharmaceutical Co.,Ltd

Equities

300026

CNE100000GF1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-07-17 EDT 5-day change 1st Jan Change
3.21 CNY +2.23% Intraday chart for Tianjin Chase Sun Pharmaceutical Co.,Ltd +4.56% -24.29%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,759 23,523 17,064 12,738 9,643 - -
Enterprise Value (EV) 1 13,759 23,523 17,064 12,738 9,643 9,643 9,643
P/E ratio 24.1 x 34 x 27 x 23.6 x 17.8 x 16.9 x 14.6 x
Yield - - 0.53% - - - -
Capitalization / Revenue - - 2.57 x 2.08 x 1.56 x 1.48 x 1.36 x
EV / Revenue - - 2.57 x 2.08 x 1.56 x 1.48 x 1.36 x
EV / EBITDA - - - 14.8 x 11 x 10.7 x 9.22 x
EV / FCF - - -690,785,883 x - - - -
FCF Yield - - -0% - - - -
Price to Book - - 2.06 x 1.46 x 1.05 x 1 x 0.95 x
Nbr of stocks (in thousands) 3,004,155 3,004,155 3,004,155 3,004,155 3,004,155 - -
Reference price 2 4.580 7.830 5.680 4.240 3.210 3.210 3.210
Announcement Date 2/25/21 2/28/22 2/27/23 2/29/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 6,650 6,127 6,194 6,511 7,083
EBITDA 1 - - - 862.5 878 904 1,046
EBIT 1 - - 712.5 511.5 603 606 723
Operating Margin - - 10.71% 8.35% 9.74% 9.31% 10.21%
Earnings before Tax (EBT) 1 - - 716.4 629 636 657 791
Net income 1 575.6 688.3 624.2 529.2 533 557 664
Net margin - - 9.39% 8.64% 8.61% 8.55% 9.37%
EPS 2 0.1900 0.2300 0.2100 0.1800 0.1800 0.1900 0.2200
Free Cash Flow - - -24.7 - - - -
FCF margin - - -0.37% - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - 0.0300 - - - -
Announcement Date 2/25/21 2/28/22 2/27/23 2/29/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - -24.7 - - - -
ROE (net income / shareholders' equity) - - 7.78% 5.97% 5.8% 5.8% 6.5%
ROA (Net income/ Total Assets) - - - 4.31% 4.3% 4.3% 4.9%
Assets 1 - - - 12,266 12,395 12,953 13,551
Book Value Per Share 2 - - 2.760 2.900 3.050 3.200 3.390
Cash Flow per Share - - - - - - -
Capex 1 - - 770 345 212 215 221
Capex / Sales - - 11.58% 5.63% 3.42% 3.3% 3.12%
Announcement Date 2/25/21 2/28/22 2/27/23 2/29/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.21 CNY
Average target price
4 CNY
Spread / Average Target
+24.61%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300026 Stock
  4. Financials Tianjin Chase Sun Pharmaceutical Co.,Ltd